KR102819951B1 - 아자벤즈이미다졸 화합물 및 의약 - Google Patents

아자벤즈이미다졸 화합물 및 의약 Download PDF

Info

Publication number
KR102819951B1
KR102819951B1 KR1020207035176A KR20207035176A KR102819951B1 KR 102819951 B1 KR102819951 B1 KR 102819951B1 KR 1020207035176 A KR1020207035176 A KR 1020207035176A KR 20207035176 A KR20207035176 A KR 20207035176A KR 102819951 B1 KR102819951 B1 KR 102819951B1
Authority
KR
South Korea
Prior art keywords
methyl
pyridin
trifluoromethyl
imidazo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207035176A
Other languages
English (en)
Korean (ko)
Other versions
KR20210006437A (ko
Inventor
고우야 오이카와
쇼 히라이
가즈히코 와키타
아키코 후지바야시
Original Assignee
니뽄 신야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니뽄 신야쿠 가부시키가이샤 filed Critical 니뽄 신야쿠 가부시키가이샤
Publication of KR20210006437A publication Critical patent/KR20210006437A/ko
Application granted granted Critical
Publication of KR102819951B1 publication Critical patent/KR102819951B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207035176A 2018-05-08 2019-05-07 아자벤즈이미다졸 화합물 및 의약 Active KR102819951B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018089867 2018-05-08
JPJP-P-2018-089867 2018-05-08
PCT/JP2019/018201 WO2019216294A1 (ja) 2018-05-08 2019-05-07 アザベンゾイミダゾール化合物及び医薬

Publications (2)

Publication Number Publication Date
KR20210006437A KR20210006437A (ko) 2021-01-18
KR102819951B1 true KR102819951B1 (ko) 2025-06-13

Family

ID=68467433

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035176A Active KR102819951B1 (ko) 2018-05-08 2019-05-07 아자벤즈이미다졸 화합물 및 의약

Country Status (35)

Country Link
US (1) US12319683B2 (cg-RX-API-DMAC10.html)
EP (1) EP3792260B1 (cg-RX-API-DMAC10.html)
JP (1) JP7235047B2 (cg-RX-API-DMAC10.html)
KR (1) KR102819951B1 (cg-RX-API-DMAC10.html)
CN (1) CN112368282B (cg-RX-API-DMAC10.html)
AU (1) AU2019265134B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020022662A2 (cg-RX-API-DMAC10.html)
CA (1) CA3099655A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020002868A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020013848A2 (cg-RX-API-DMAC10.html)
DK (1) DK3792260T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP20078586A (cg-RX-API-DMAC10.html)
ES (1) ES2992256T3 (cg-RX-API-DMAC10.html)
FI (1) FI3792260T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241414T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068695T2 (cg-RX-API-DMAC10.html)
IL (1) IL278517B2 (cg-RX-API-DMAC10.html)
LT (1) LT3792260T (cg-RX-API-DMAC10.html)
MA (1) MA52587B1 (cg-RX-API-DMAC10.html)
MD (1) MD3792260T2 (cg-RX-API-DMAC10.html)
MX (1) MX2020011855A (cg-RX-API-DMAC10.html)
MY (1) MY202833A (cg-RX-API-DMAC10.html)
PE (1) PE20211384A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020551873A1 (cg-RX-API-DMAC10.html)
PL (1) PL3792260T3 (cg-RX-API-DMAC10.html)
PT (1) PT3792260T (cg-RX-API-DMAC10.html)
RS (1) RS65996B1 (cg-RX-API-DMAC10.html)
SA (1) SA520420487B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202011003TA (cg-RX-API-DMAC10.html)
SI (1) SI3792260T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400407T1 (cg-RX-API-DMAC10.html)
TW (1) TWI868068B (cg-RX-API-DMAC10.html)
UA (1) UA126774C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019216294A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202007164B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3160838A1 (en) * 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Therapeutic agents and prophylactic agents for functional gastrointestinal disorders and xerostomia
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
CN118045050B (zh) * 2023-11-16 2025-06-10 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种头颈部放疗患者适用的缓解口腔干燥的组合物及其制备方法
CN122422310A (zh) * 2024-01-17 2026-07-17 盛睿泽华医药科技(苏州)有限公司 可溶性环氧水解酶抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545779A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン
JP2016509048A (ja) 2013-02-20 2016-03-24 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited アスパラギンメチル転移酵素の阻害剤としての2−(ヘテロ)アリールベンゾイミダゾール及びイミダゾピリジン誘導体

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723142A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
EP1734820A4 (en) 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP2054405B1 (en) 2006-07-11 2013-09-18 Daewoong Pharmaceutical Co., Ltd. Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
EA201001205A1 (ru) 2008-01-24 2011-04-29 Юсб Фарма, С.А. Соединения, содержащие циклобутоксигруппу
US9085507B2 (en) 2009-05-11 2015-07-21 Ratiopharm Gmbh Desfesoterodine in the form of a tartaric acid salt
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規2環性複素環化合物からなる医薬
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
MY166889A (en) 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
JP2013237634A (ja) 2012-05-14 2013-11-28 Dainippon Sumitomo Pharma Co Ltd 縮環イミダゾロン誘導体
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽
MX370140B (es) 2014-06-06 2019-12-03 Astellas Pharma Inc Derivado de 2-acilaminotiazol o sal del mismo.
JP6569678B2 (ja) 2014-08-26 2019-09-04 アステラス製薬株式会社 2−アミノチアゾール誘導体またはその塩
EP3290037A4 (en) 2015-04-28 2019-01-23 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018157857A1 (zh) 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
JP7291632B2 (ja) 2017-12-21 2023-06-15 杏林製薬株式会社 夜間頻尿治療剤
JPWO2019189766A1 (ja) 2018-03-30 2021-04-08 持田製薬株式会社 新規ビアリールアミド誘導体
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3160838A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Therapeutic agents and prophylactic agents for functional gastrointestinal disorders and xerostomia
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545779A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン
JP2016509048A (ja) 2013-02-20 2016-03-24 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited アスパラギンメチル転移酵素の阻害剤としての2−(ヘテロ)アリールベンゾイミダゾール及びイミダゾピリジン誘導体

Also Published As

Publication number Publication date
BR112020022662A2 (pt) 2021-02-09
MX2020011855A (es) 2021-01-20
MA52587B1 (fr) 2024-10-31
SA520420487B1 (ar) 2024-03-17
EP3792260B1 (en) 2024-09-11
KR20210006437A (ko) 2021-01-18
LT3792260T (lt) 2024-10-25
AU2019265134A1 (en) 2020-12-17
EP3792260A4 (en) 2022-02-09
DK3792260T3 (da) 2024-10-14
AU2019265134B2 (en) 2024-02-29
US12319683B2 (en) 2025-06-03
IL278517A (en) 2020-12-31
HUE068695T2 (hu) 2025-01-28
PH12020551873A1 (en) 2021-05-31
PL3792260T3 (pl) 2024-12-02
US20210371412A1 (en) 2021-12-02
IL278517B1 (en) 2024-05-01
IL278517B2 (en) 2024-09-01
ES2992256T3 (es) 2024-12-11
PT3792260T (pt) 2024-10-02
TWI868068B (zh) 2025-01-01
WO2019216294A1 (ja) 2019-11-14
EP3792260A1 (en) 2021-03-17
CN112368282A (zh) 2021-02-12
SMT202400407T1 (it) 2024-11-15
JPWO2019216294A1 (ja) 2021-05-13
MD3792260T2 (ro) 2024-12-31
CL2020002868A1 (es) 2021-04-16
CO2020013848A2 (es) 2021-01-29
CA3099655A1 (en) 2019-11-14
TW202016108A (zh) 2020-05-01
MA52587A (fr) 2021-03-17
ECSP20078586A (es) 2021-01-29
CN112368282B (zh) 2023-10-13
UA126774C2 (uk) 2023-02-01
JP7235047B2 (ja) 2023-03-08
HRP20241414T1 (hr) 2024-12-20
FI3792260T3 (fi) 2024-10-01
ZA202007164B (en) 2024-06-26
PE20211384A1 (es) 2021-07-27
SG11202011003TA (en) 2020-12-30
MY202833A (en) 2024-05-24
SI3792260T1 (sl) 2024-11-29
RS65996B1 (sr) 2024-10-31

Similar Documents

Publication Publication Date Title
US8822448B2 (en) Pyrazoloquinoline compound
CN112368282B (zh) 氮杂苯并咪唑化合物和医药
KR102951288B1 (ko) 아자벤즈이미다졸 화합물 및 의약
US20220324863A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
RU2804485C2 (ru) Азабензимидазольные соединения и фармкомпозиция
HK40045733A (en) Azabenzimidazole compounds and pharmaceutical
HK40045733B (en) Azabenzimidazole compounds and pharmaceutical
HK40046611A (en) Azabenzimidazole compounds and pharmaceutical
HK40046611B (en) Azabenzimidazole compounds and pharmaceutical
HK40075503A (en) Azabenzimidazole compound and medicine
HK40076325A (en) Azabenzimidazole compound and medicine
CN121605108A (zh) 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用
EA039324B1 (ru) 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220321

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240305

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250313

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250609

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250610

End annual number: 3

Start annual number: 1

PG1601 Publication of registration